尤瑞克林对高龄急性脑梗死患者血清纤溶酶原激活物抑制物1表达的影响(1)
[摘要] 目的 探討尤瑞克林对高龄急性脑梗死患者血清纤溶酶原激活物抑制物-1(PAI-1)的影响。 方法 收集2016年1月～2018年12月于解放军联勤保障部队第九〇三医院老年病诊治中心住院的98例急性脑梗死患者，随机分为两组，尤瑞克林组50例，对照组48例。对照组和尤瑞克林组均给予相同的脑梗死常规治疗，尤瑞克林组除常规治疗外，加用尤瑞克林治疗，方法是在0.9%氯化钠注射液100 mL中加入尤瑞克林0.15PNA，1次/天，滴注时间不少于50 min，治疗21 d。分别于治疗前、治疗7 d、21 d时检测血清PAI-1浓度的变化，并同时进行临床神经功能缺损评分。 结果 两组患者治疗前血清PAI-1浓度无明显差异，二者具有可比性，治疗后血清PAI-1浓度均较治疗前明显降低，差异有统计学意义(P<0.05)，与对照组7 d、21 d相比，尤瑞克林组治疗相应时间血清PAI-1浓度下降更明显，差异有统计学意义(P<0.05)。两组治疗21 d后神经功能缺损评分均有不同程度改善，尤瑞克林组较对照组改善更明显(P<0.05)。 结论 尤瑞克林可明显降低血清PAI-1水平，同时明显改善NIHSS评分，提示尤瑞克林可能通过降低血浆中PAI-1的浓度、改善纤溶功能，从而改善患者预后。
[关键词] 尤瑞克林;急性脑梗死;高龄;纤溶酶原激活物抑制物1;神经功能缺损评分
[中图分类号] R743.3 [文献标识码] A [文章编号] 1673-9701(2020)25-0029-04
Effect of eureklin on expression of serum plasminogen activator inhibitor 1 in elderly patients with acute cerebral infarction
XU Juan1 DAI Yi2 SANG Hongfei3 LI Hong4 CHEN Xiaona4
1.Department of Endocrinology， Hangzhou First People's Hospital affiliated to Zhejiang University Medical College， Hangzhou 310007， China; 2.Department of Neurology， the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army， Hangzhou 310013， China; 3.Department of Neurology， Hangzhou First People's Hospital affiliated to Zhejiang University Medical College， Hangzhou 310007， China; 4.Geriatric Disease Diagnosis and Treatment Center， the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army， Hangzhou 310013， China
[Abstract] Objective To investigate the effect of eureklin on serum plasminogen activator inhibitor-1(PAI-1) in elderly patients with acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction in the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army from January 2016 to December 2018 were collected and randomly divided into two groups including 50 patients in the eureklin group and 48 patients in the control group. The two groups were given the same routine treatment for cerebral infarction. The eureklin group was added with 0.15PNA in 0.9% sodium chloride injection 100 mL in addition to the routine treatment， once per day， and the infusion time was not less than 50 minutes. The treatment lasted for 21 days. Serum PAI-1 concentration was measured before treatment， 7 days after treatment， and 21 days after treatment. At the same time， the clinical neurological deficit score was also evaluated. Results There was significant difference in the serum concentration of PAI-1 between two groups before treatment. The PAI-1 after treatment was significantly lower than that before treatment， and the difference was statistically significant(P<0.05). Compared with that of the control group after treatment for 7 d and 21 d， serum concentration of PAI-1 in eureklin group decreased more significantly， and the difference was significant(P<0.05). After 21 days of treatment， neurological deficits in both groups were improved to varying degrees， and the improvement was more obvious in the eureklin group than in the control group(P<0.05). Conclusions eureklin can significantly reduce serum PAI-1 level and improve NIHSS score， suggesting that eureklin may improve the prognosis of patients by reducing plasma PAI-1 concentration and improving fibrinolysis., 百拇医药(许娟 戴毅 桑红菲 郦虹 陈晓娜)
[关键词] 尤瑞克林;急性脑梗死;高龄;纤溶酶原激活物抑制物1;神经功能缺损评分
[中图分类号] R743.3 [文献标识码] A [文章编号] 1673-9701(2020)25-0029-04
Effect of eureklin on expression of serum plasminogen activator inhibitor 1 in elderly patients with acute cerebral infarction
XU Juan1 DAI Yi2 SANG Hongfei3 LI Hong4 CHEN Xiaona4
1.Department of Endocrinology， Hangzhou First People's Hospital affiliated to Zhejiang University Medical College， Hangzhou 310007， China; 2.Department of Neurology， the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army， Hangzhou 310013， China; 3.Department of Neurology， Hangzhou First People's Hospital affiliated to Zhejiang University Medical College， Hangzhou 310007， China; 4.Geriatric Disease Diagnosis and Treatment Center， the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army， Hangzhou 310013， China
[Abstract] Objective To investigate the effect of eureklin on serum plasminogen activator inhibitor-1(PAI-1) in elderly patients with acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction in the 903th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army from January 2016 to December 2018 were collected and randomly divided into two groups including 50 patients in the eureklin group and 48 patients in the control group. The two groups were given the same routine treatment for cerebral infarction. The eureklin group was added with 0.15PNA in 0.9% sodium chloride injection 100 mL in addition to the routine treatment， once per day， and the infusion time was not less than 50 minutes. The treatment lasted for 21 days. Serum PAI-1 concentration was measured before treatment， 7 days after treatment， and 21 days after treatment. At the same time， the clinical neurological deficit score was also evaluated. Results There was significant difference in the serum concentration of PAI-1 between two groups before treatment. The PAI-1 after treatment was significantly lower than that before treatment， and the difference was statistically significant(P<0.05). Compared with that of the control group after treatment for 7 d and 21 d， serum concentration of PAI-1 in eureklin group decreased more significantly， and the difference was significant(P<0.05). After 21 days of treatment， neurological deficits in both groups were improved to varying degrees， and the improvement was more obvious in the eureklin group than in the control group(P<0.05). Conclusions eureklin can significantly reduce serum PAI-1 level and improve NIHSS score， suggesting that eureklin may improve the prognosis of patients by reducing plasma PAI-1 concentration and improving fibrinolysis., 百拇医药(许娟 戴毅 桑红菲 郦虹 陈晓娜)